エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 21, 2025
iSpecimen Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40501 | 27-0480143 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
8 Cabot Road, Suite 1800
Woburn, MA 01801
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (781) 301-6700
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, par value $0.0001 per share | ISPC | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On August 21, 2025, iSpecimen Inc. (the “Company”) issued a press release announcing the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This achievement marks the installation of the new Salestack platform and provisioning of modern infrastructure. The Company is now positioned to advance to Milestone 2 (Integration), which will focus on connecting all parts of the Company’s business to the Salestack platform to create end-to-end efficiency across operations, customer engagement, and data management.
A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated August 21, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 21, 2025
| iSPECIMEN INC. | |||
| By: | /s/ Robert Bradley Lim | ||
| Name: | Robert Bradley Lim | ||
| Title: | Chief Executive Officer | ||
Exhibit 99.1
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform
Woburn, MA – August 21, 2025 – iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.
Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack’s next-generation, cloud-native architecture, expected to deliver immediate value through:
| ● | Infrastructure-as-Code (IaC): built to be automated and a more secure and error-free infrastructure that replaces legacy manual processes. |
| ● | Unified Storage & Workflows: Centralized, scalable code management for all projects and services, reducing silos and technical debt. |
| ● | Future-Ready Foundation: One-click deployment, automated security, and seamless integration with AWS, GCP, and Azure. |
With this installation complete, the iSpecimen Marketplace® now operates on a modernized digital backbone that is designed to ensure reliability, scalability, and faster time-to-market.
“The successful completion of Milestone 1 is a major step forward in iSpecimen’s mission to create the most efficient and secure marketplace in our industry,” said Robert Lim, CEO of iSpecimen. “By leveraging Salestack’s advanced platform, we are working to future-proof our systems, eliminating long-standing inefficiencies, and preparing for the next phases of integration, customization, and automation.”
The completion of Milestone 1 is expected to provide several immediate and long-term benefits significant to the Company:
| 1. | Improved Reliability: Resilient, multi-cloud architecture reduces risk of outages and downtime. |
| 2. | Enhanced Security: Automated safeguards designed to eliminate vulnerabilities from manual provisioning. |
| 3. | Accelerated Innovation: Development cycles are faster, enabling quicker delivery of features to customers and stakeholders. |
This accomplishment positions iSpecimen to advance to Milestone 2 (Integration), which will focus on connecting all parts of the Company’s business to the Salestack platform to create end-to-end efficiency across operations, customer engagement, and data management.
“With Milestone 1 complete, we have implemented a robust and scalable platform that sets the stage for innovation,” continued Mr. Lim. “As we progress through the next milestones, we expect to unlock even greater efficiencies, enhance our marketplace capabilities, with the goal of creating significant long-term value for our shareholders, partners, and customers,” he concluded.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; the inability or difficulty to obtain planned benefits from the Company’s digital transformation program powered by Salestack Solutions; and risks and uncertainties associated with market conditions and the Company’s ability to meet future milestones with Salestack. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contacts:
info@ispecimen.com